Compare $ATNM vs $CLCS | Chartloom

Compare

$ATNM vs $CLCS

Actinium Pharmaceuticals Inc · Cell Source Inc

ATNM

Actinium Pharmaceuticals Inc

CLCS

Cell Source Inc

Compare $ATNM vs $CLCS

Comparing Actinium Pharmaceuticals Inc and Cell Source Inc

ATNMActinium Pharmaceuticals Inc

CLCSCell Source Inc

ATNMActinium Pharmaceuticals Inc

Market cap

$35M

P/E (TTM)

3.06x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-19.7%

52W performance

-28.6%

FCF yield

-67.4%

CLCSCell Source Inc

Market cap

$37M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-9.1%

52W performance

76.1%

FCF yield

-8.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ATNM

CLCS

Detailed metrics comparison

ATNM

Actinium Pharmaceuticals Inc

CLCS

Cell Source Inc

Market Cap

ATNM$35M

CLCS$37M

Enterprise Value

ATNM$-2M

CLCS$48M

Price

ATNM$1.10

CLCS$0.55

P/E Ratio

ATNM3.06x

CLCSN/A

P/S Ratio

ATNM0.98x

CLCS0.00x

EV/Sales

ATNM-0.06x

CLCS0.00x

EV/EBITDA

ATNM-0.20x

CLCS0.00x

P/B Ratio

ATNM1.21x

CLCSN/A

P/FCF Ratio

ATNMN/A

CLCSN/A

EV/FCF

ATNM0.08x

CLCS-15.29x

PEG Ratio

ATNMN/A

CLCSN/A

Forward P/E (NTM)

ATNMN/A

CLCSN/A

Forward P/S (NTM)

ATNMN/A

CLCSN/A

Revenue (TTM)

ATNM$35M

CLCS$0

Revenue Growth (YoY)

ATNMN/A

CLCSN/A

Forward Rev Growth

ATNM-0.2%

CLCS0.0%

Gross Margin (TTM)

ATNM0.0%

CLCS0.0%

Operating Margin (TTM)

ATNM62.3%

CLCS0.0%

EBITDA Margin (TTM)

ATNM27.9%

CLCS0.0%

Net Margin (TTM)

ATNM32.2%

CLCS0.0%

FCF Margin (TTM)

ATNM-66.2%

CLCSN/A

Net Income (TTM)

ATNM$11M

CLCS$-6M

FCF (TTM)

ATNM$-23M

CLCS$-3M

EPS (TTM)

ATNM$0.36

CLCS-$0.14

ROE (TTM)

ATNM83.4%

CLCS-184198.9%

ROA (TTM)

ATNM23.4%

CLCS-148238.0%

ROIC (TTM)

ATNM83.4%

CLCS0.0%

Cash

ATNM$36M

CLCS$1K

Debt

ATNM$5K

CLCS$11M

Net Cash/Debt

ATNM$36M

CLCS$-10M

Current Ratio (TTM)

ATNM4.08x

CLCS0.01x

Quick Ratio (TTM)

ATNM3.94x

CLCS0.00x

Debt/Equity (TTM)

ATNM0.00x

CLCS0.00x

Debt/Assets (TTM)

ATNM0.0%

CLCS0.0%

Interest Coverage (TTM)

ATNMN/A

CLCSN/A

Net Debt/EBITDA (TTM)

ATNM0.00x

CLCS0.00x

Beta

ATNM0.33

CLCS24.04

52W Performance

ATNM-28.6%

CLCS76.1%

YTD Performance

ATNM-19.7%

CLCS-9.1%

% from 52W High

ATNM-36.8%

CLCS-75.8%

% from 52W Low

ATNM49.6%

CLCS199.8%

Asset Turnover (TTM)

ATNM0.73x

CLCS0.00x

FCF Yield (TTM)

ATNM-67.4%

CLCS-8.4%

Earnings Yield (TTM)

ATNM32.8%

CLCS-16.5%

Dividend Yield (TTM)

ATNMN/A

CLCSN/A

Rule of 40

ATNM-66.2

CLCS0.0

EV/GP/RG

ATNMN/A

CLCSN/A

Ticker research

View ATNM research View CLCS research

Metric	ATNM Actinium Pharmaceuticals Inc	CLCS Cell Source Inc
Market & Valuation
Market Cap	$35M	$37M
Enterprise Value	$-2M	$48M
Price	$1.10	$0.55
P/E Ratio	3.06x	N/A
P/S Ratio	0.98x	0.00x
EV/Sales	-0.06x	0.00x
EV/EBITDA	-0.20x	0.00x
P/B Ratio	1.21x	N/A
P/FCF Ratio	N/A	N/A
EV/FCF	0.08x	-15.29x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$35M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	-0.2%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	62.3%	0.0%
EBITDA Margin (TTM)	27.9%	0.0%
Net Margin (TTM)	32.2%	0.0%
FCF Margin (TTM)	-66.2%	N/A
Net Income (TTM)	$11M	$-6M
FCF (TTM)	$-23M	$-3M
EPS (TTM)	$0.36	-$0.14
ROE (TTM)	83.4%	-184198.9%
ROA (TTM)	23.4%	-148238.0%
ROIC (TTM)	83.4%	0.0%
Financial Health
Cash	$36M	$1K
Debt	$5K	$11M
Net Cash/Debt	$36M	$-10M
Current Ratio (TTM)	4.08x	0.01x
Quick Ratio (TTM)	3.94x	0.00x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.33	24.04
52W Performance	-28.6%	76.1%
YTD Performance	-19.7%	-9.1%
% from 52W High	-36.8%	-75.8%
% from 52W Low	49.6%	199.8%
Efficiency & Yields
Asset Turnover (TTM)	0.73x	0.00x
FCF Yield (TTM)	-67.4%	-8.4%
Earnings Yield (TTM)	32.8%	-16.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-66.2	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ATNM research	View CLCS research

Valuation

P/E Ratio

ATNM

3.06x

P/S Ratio

CLCS

0.00x

ATNM

0.98x

EV/FCF

CLCS

-15.29x

ATNM

0.08x

Growth & revenue

Forward Revenue Growth

CLCS

0.0%

ATNM

-0.2%

Profitability & performance

Gross Margin

ATNM

0.0%

CLCS

0.0%

ROE

ATNM

83.4%

CLCS

-184198.9%

FCF Yield %

CLCS

-8.4%

ATNM

-67.4%

52-Week Performance

CLCS

76.1%

ATNM

-28.6%

Detailed metrics comparison

ATNM

Actinium Pharmaceuticals Inc

CLCS

Cell Source Inc

Market Cap

ATNM$35M

CLCS$37M

Enterprise Value

ATNM$-2M

CLCS$48M

Price

ATNM$1.10

CLCS$0.55

P/E Ratio

ATNM3.06x

CLCSN/A

P/S Ratio

ATNM0.98x

CLCS0.00x

EV/Sales

ATNM-0.06x

CLCS0.00x

EV/EBITDA

ATNM-0.20x

CLCS0.00x

P/B Ratio

ATNM1.21x

CLCSN/A

P/FCF Ratio

ATNMN/A

CLCSN/A

EV/FCF

ATNM0.08x

CLCS-15.29x

PEG Ratio

ATNMN/A

CLCSN/A

Forward P/E (NTM)

ATNMN/A

CLCSN/A

Forward P/S (NTM)

ATNMN/A

CLCSN/A

Revenue (TTM)

ATNM$35M

CLCS$0

Revenue Growth (YoY)

ATNMN/A

CLCSN/A

Forward Rev Growth

ATNM-0.2%

CLCS0.0%

Gross Margin (TTM)

ATNM0.0%

CLCS0.0%

Operating Margin (TTM)

ATNM62.3%

CLCS0.0%

EBITDA Margin (TTM)

ATNM27.9%

CLCS0.0%

Net Margin (TTM)

ATNM32.2%

CLCS0.0%

FCF Margin (TTM)

ATNM-66.2%

CLCSN/A

Net Income (TTM)

ATNM$11M

CLCS$-6M

FCF (TTM)

ATNM$-23M

CLCS$-3M

EPS (TTM)

ATNM$0.36

CLCS-$0.14

ROE (TTM)

ATNM83.4%

CLCS-184198.9%

ROA (TTM)

ATNM23.4%

CLCS-148238.0%

ROIC (TTM)

ATNM83.4%

CLCS0.0%

Cash

ATNM$36M

CLCS$1K

Debt

ATNM$5K

CLCS$11M

Net Cash/Debt

ATNM$36M

CLCS$-10M

Current Ratio (TTM)

ATNM4.08x

CLCS0.01x

Quick Ratio (TTM)

ATNM3.94x

CLCS0.00x

Debt/Equity (TTM)

ATNM0.00x

CLCS0.00x

Debt/Assets (TTM)

ATNM0.0%

CLCS0.0%

Interest Coverage (TTM)

ATNMN/A

CLCSN/A

Net Debt/EBITDA (TTM)

ATNM0.00x

CLCS0.00x

Beta

ATNM0.33

CLCS24.04

52W Performance

ATNM-28.6%

CLCS76.1%

YTD Performance

ATNM-19.7%

CLCS-9.1%

% from 52W High

ATNM-36.8%

CLCS-75.8%

% from 52W Low

ATNM49.6%

CLCS199.8%

Asset Turnover (TTM)

ATNM0.73x

CLCS0.00x

FCF Yield (TTM)

ATNM-67.4%

CLCS-8.4%

Earnings Yield (TTM)

ATNM32.8%

CLCS-16.5%

Dividend Yield (TTM)

ATNMN/A

CLCSN/A

Rule of 40

ATNM-66.2

CLCS0.0

EV/GP/RG

ATNMN/A

CLCSN/A

Ticker research

View ATNM research View CLCS research

Metric	ATNM Actinium Pharmaceuticals Inc	CLCS Cell Source Inc
Market & Valuation
Market Cap	$35M	$37M
Enterprise Value	$-2M	$48M
Price	$1.10	$0.55
P/E Ratio	3.06x	N/A
P/S Ratio	0.98x	0.00x
EV/Sales	-0.06x	0.00x
EV/EBITDA	-0.20x	0.00x
P/B Ratio	1.21x	N/A
P/FCF Ratio	N/A	N/A
EV/FCF	0.08x	-15.29x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$35M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	-0.2%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	62.3%	0.0%
EBITDA Margin (TTM)	27.9%	0.0%
Net Margin (TTM)	32.2%	0.0%
FCF Margin (TTM)	-66.2%	N/A
Net Income (TTM)	$11M	$-6M
FCF (TTM)	$-23M	$-3M
EPS (TTM)	$0.36	-$0.14
ROE (TTM)	83.4%	-184198.9%
ROA (TTM)	23.4%	-148238.0%
ROIC (TTM)	83.4%	0.0%
Financial Health
Cash	$36M	$1K
Debt	$5K	$11M
Net Cash/Debt	$36M	$-10M
Current Ratio (TTM)	4.08x	0.01x
Quick Ratio (TTM)	3.94x	0.00x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.33	24.04
52W Performance	-28.6%	76.1%
YTD Performance	-19.7%	-9.1%
% from 52W High	-36.8%	-75.8%
% from 52W Low	49.6%	199.8%
Efficiency & Yields
Asset Turnover (TTM)	0.73x	0.00x
FCF Yield (TTM)	-67.4%	-8.4%
Earnings Yield (TTM)	32.8%	-16.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-66.2	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ATNM research	View CLCS research